Towards New Broader Spectrum Pneumococcal Vaccines: The Future of Pneumococcal Disease Prevention.
Seven-valent pneumococcal conjugate vaccine (PCV7) introduction and routine pediatric use has substantially reduced the burden of Streptococcus pneumoniae disease worldwide. However, a significant amount of disease burden, due to serotypes not contained in PCV7, still exists globally. A newly recognized serotype, 6C, was until recently, identified and reported as serotype 6A. This review summarizes the serotype epidemiology of pneumococcal disease pre- and post-introduction of PCV7, available post-marketing surveillance data following the introduction of higher valency pneumococcal vaccines (PCV10, PCV13) and future prospects for the development of new pneumococcal vaccines.
Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, MD 20852, USA. Lucia.Lee@fda.hhs.gov.
Lucia H
LH
Lee
National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA. guxx@niaid.nih.gov.
Xin-Xing
XX
Gu
Departments of Microbiology and Pathology, University of Alabama at Birmingham, Birmingham, AL 35233, USA. nahm@uab.edu.
Moon H
MH
Nahm
Streptococcus pneumoniae; epidemiology; pneumococcal protein; serotype; vaccine